brought to you by T CORE

Naunyn-Schmiedeberg's Arch Pharmacol DOI 10.1007/s00210-015-1191-5

32

5 6 REVIEW

4 **Natural compounds for pediatric cancer treatment**

Veronica Ferrucci^{1,2} · Iolanda Boffa^{1,3} · Gina De Masi^{1,3} · Massimo Zollo^{1,2,3}

7 Received: 27 October 2015 / Accepted: 8 November 2015

8 © Springer-Verlag Berlin Heidelberg 2015

Abstract There is a tremendous need in clinics to impair 9 10cancer progression through noninvasive therapeutic approaches. The use of natural compounds to achieve this is of 11 importance to improve the quality of life of young patients 1213during their treatments. This review will address the "status of the art" related to the potential of natural compounds that 14are undergoing investigation in combination with standard 1516therapeutic protocols in preclinical and clinical studies and their importance for pediatric cancer treatment. The early stud-1718 ies of drug discovery of these natural compounds discussed 19 here include the main targets, the cellular signaling pathways 20involved, and the potential modes of action. We also focus on some promising natural compounds that have shown excellent 21results in vitro and in vivo: Chebulagic acid, Apigenin, 2223Norcantharidin, Saffron/Crocin, Parthenolide, Longikaurin E, Lupeol, Spongistatin 1, and Deoxy-variolin B. Additional-24ly, we introduce the effects of several compounds from nutra-25ceutical and functional foods, to underline their potential use 2627as adjuvant therapies to improve therapeutic benefits. For this purpose, we have selected several compounds: Agaritine, 28Ganoderma and GL6 peptide, Diallyl trisulfide and Ajoene 29

Electronic supplementary material The online version of this article (doi:10.1007/s00210-015-1191-5) contains supplementary material, which is available to authorized users.

Massimo Zollo massimo.zollo@unina.it

01

- ¹ Department of Molecular Medicine and Medical Biotechnology, 'Federico II' University of Naples, Via Pansini 5, Naples, Italy
- ² European School of Molecular Medicine (SEMM), Milan, Italy
- ³ Ceinge Biotecnologie Avanzate, Via Gaetano Salvatore 486, Naples, Italy

from ga	arlic, Epigallocatechin gallate from green tea,	30					
Curcum	in, Resveratrol, and Quercetin.	31					
Keywor	ds Anti-cancer drugs · Natural compounds ·	32					
Functional foods · Nutraceuticals · Pediatric tumors · Side							
effects · Tumorigenic pathways							
Abbrev	iations	35					
EGCG	Epigallocatechin gallate	38					
IAPs	Inhibitor-of-apoptosis proteins	39					
RGD	Arginine-lysine-aspartate	43					

Introduction

Advances in therapeutic strategies based on small synthetic45molecules and/or monoclonal humanized antibodies designed46for inhibition of signaling pathways can often produce toxicity47in vivo. Thus, the development of non-toxic molecules that48target specific genes or proteins should be the strategy for the49near future.50

Natural compounds are small molecules that are produced 51by a biological source, from plants, animals, marine organ-52isms, and microorganisms (Watkins et al. 2015). The introduc-53tion of natural agents into cancer treatments has been helpful 54for many types of malignancies. Indeed, over 60 % of ap-55proved anti-tumorigenic drugs derive from natural sources 56(da Rocha et al. 2001, Mann 2002). The anti-tumorigenic 57agents derived from plants and microorganisms currently used 58in clinics in pediatric oncology are listed in Table 1. 59

However, not all of the characterization studies of natural60compounds identified worldwide follow the regulation guide-61lines. Indeed, only those natural compounds that show a spe-62cific biologically active ingredient in, for example, a plant63

Q2 t1.1	Table 1 shown	therapeutic products der	rived from plant and microbi	ial extracts currently used as an	Chemotherapeutic products derived from plant and microbial extracts currently used as anti-cancer drugs. The main features of natural compounds used in clinical trials for childhood tumors are	compounds used in cli	inical trials for childhood tumors are	S - P
t1.2	Name	Molecular formula	Target	Toxicity	Clinical trials	Doses	Reference	₩1-
t1.3	Vincristine	$C_{46}H_{56}N_4O_{10}$	Mitotic spindle	Granulocytopenia Thrombocytopenia	Hematological neoplasms Neuroblastoma Madull-Mostoma	$1-2 \text{ mg/m}^2$	(Rubie, De Bernardi et al. 2011) (De Moerloose, Suciu et al. 2010))(13 7
t1.4	Vinblastine	$C_{46}H_{58}N_4O_9$	Mitotic spindle	Neurotoxicity Hypertension Neurotoxicity	Protonopasona Hodgkin's disease Lymphomas Sarcomas	2.5-6 mg/m ²	(Bates, Danilov et al. 2013) (Salerni, Bates et al. 2010)	02/00
t1.5	Paclitaxel	$\mathrm{C}_{47}\mathrm{H}_{51}\mathrm{NO}_{14}$	Mitotic spindle	Neutropenia	Intracranial germ cell tumors Sarcoma Namohlacroma	250–350 mg/m ²	(Geller, Wall et al. 2009)	Q7
t1.6	i Irinotecan	$C_{33}H_{38}N_4O_6$	DNA topoisomerase I	Neutropenia Gastrointestinal disorders Hypersensibility	Rhabdomyosarcoma Neuroblastoma Medulloblastoma Frondumoma	25–130 mg/m ²	(Turner, Gururangan et al. 2002) (Ma and McLeod 2003) (Kim, Kang et al. 2013)	Q8/Q9 Q10
t1.7	Topotecan	$C_{23}H_{23}N_{3}O$	DNA topoisomerase I	Hematotoxicity Gastrointestinal disorders	Neuroblastoma Rhabdomyosarcoma	$0.75{-}1.5 \text{ mg/m}^2$	(Feng, Tang et al. 2013)	Q11
t1.8	Etoposide	C ₂₉ H ₃₂ O ₁₃	Cell cycle	Dermauovatory Myelosuppression Alopecia Gastrointestinal disorders	Neuroblastoma Lymphomas Leukemia	60–150 mg/m ²	(Najar and Johri 2014) (Wagner, Hill et al. 2002) (Kushner, Modak et al. 2013)	Q12/Q13 Q14
t1.9	Daunorubicin	$C_{27}H_{29}NO_{10}$	DNA topoisomerase II	Bone marrow depression Gastrointestinal disorders	Leukemia Leukemia Hodgkin's/non-Hodgkin's diseases	25-45 mg/m ²	(Nickel, Keller et al. 2014)	Q15
t1.1	t1.10 Idarubicin	$C_{26}H_2\gamma NO_9$	DNA topoisomerase II	Myelosuppressions Cardiotoxicity	Sarcontas Acute myeloid leukemia Relapsed acute lymphoblastic leukemia Medullichlastoma	5–12 mg/m ²	(Dreyer, Kadota et al. 2003) (Sekine, Morais et al. 2014)	910 Naun
t1.1	t1.11 Actinomycin D	C ₆₂ H ₈₆ N ₁₂ O ₁₆	Protein synthesis	Myelosuppression Hypersensitivity Gastrointestinal disorders	Rhabdomyosarcoma Ewing's sarcoma	15-600 µg/m²	(Graf, van Tinteren et al. 2012)	yn-Schmiedet

Naunyn-Schmiedeberg's Arch Pharmacol

extract, rather than the crude extract, and those for which clear 64 molecular signaling and biological effects are evident should 65be considered. Moreover, the identification of novel natural 66 67 extracts must always provide the correct botanical plant and 68 family names from which it is derived, the methods for its extraction, and its physicochemical properties (Michel et al. 69 70 2005). Taking all of these considerations into account, for the selection of the most promising natural compounds here, we 71have used this description to include only those that have 7273 followed these strict rules. One additional important point is their use in combinatorial therapies, to reduce side effects of 7475defined drugs, with the awareness that they can improve a child's outcome during treatment. 76

However, the vast majority of the anti-tumor drugs are only 77approved for the treatment of adults and not for pediatric can-78cers. The main reason for this is that targeting pediatric can-79cers is a "small market" for investment (Hirschfeld et al. 80 2003). Moreover, pediatric cancers can be driven by molecu-81 82 lar mechanisms that are different from those responsible for adult tumors (Smith and Reaman 2015); this makes it more 83 difficult to find specific drugs for childhood tumor treatment. 84

There is a growing body of literature that shows the impor-85 86 tance of natural compounds. Indeed, a large number of natural products have been found to inhibit different pathways that 87 contribute to tumorigenesis, angiogenesis, and metastasis in 88 89 childhood tumors (including those that originate from brain, bone, and liver), both in vitro and in vivo. Their main mech-90 anisms of action involve disruption of the mitotic spindle as-9192sembly, inhibition of DNA topoisomerase, arrest of cell-cycle 93 progression, induction of apoptosis, decrease of telomerase activity, and elimination of the "tumor-initiating cells" that 9495are often responsible for chemotherapeutic resistance and tu-96 mor relapse.

97 Taking all of these observations into account, pediatric tu-98 mors are generally treated equally following standard proto-99cols after surgery, using combined radiotherapy and chemotherapy. However, restricted therapeutic choices and multi-100 101drug resistance have limited the benefit of many treatments for children because of their devastating side effects, which 102 can include non-selective mechanisms of cell killing (e.g., 103104 young patients have frequently been left with severe myelosuppression); gastrointestinal toxicity; neurological def-105icit; endocrine dysfunction; and cognitive difficulties that can 106107 lead to postsurgery-related psychological problems (Kinahan et al. 2012); Anderson 2003); (Brydoy et al. 2007). Moreover, 108complete tumor resection is often difficult, and the responses 109110to radiotherapy and chemotherapy are not always efficient because of the resistance acquired by tumorigenic cells. 111

Another problem is related to the ability of current chemotherapeutics to pass the blood–brain barrier. Despite aggressive and multimodal therapies that have recently been developed, many tumors remain unaffected by these treatments and continue to have poor outcomes for children with metastatic or recurrent disease, and thus natural compounds might have the 117 potential to fill these gaps (Giangaspero, Perilongo et al. 1999; 118**Q19** 119 **Q20 Q21** 120**Q22** Schwab, Westermann et al. 2003; Blonski, Taillandier et al. 2012; Taylor, Northcott et al. 2012; Urbanska, Sokolowska 121 **Q23** et al. 2014; (da Rocha et al. 2001, Litten and Tomlinson 2008, HaDuong et al. 2015). Through their remarkable chem-122ical and structural diversity, agents derived from natural prod-123ucts continue to be of relevance as sources of drug leads that 124act as templates for the construction of novel molecules, with 125the challenge being to reduce their side effects (Koehn and 126Carter 2005). 127

In this review, we discuss nature-derived drugs that are 128emerging in the treatment of pediatric tumors, through litera-129ture searches of PubMed (http://www.ncbi.nlm.nih.gov/ 130pubmed) for the year 2015, with the scheme applied 131described in Supplementary Figure S1. Most importantly, 132these compounds are considered along with their mechanisms 133of action in tumorigenic cells, for their application as pediatric 134therapies. 135

Natural compounds in plants applied to adult clinical136cancer trials that are of interest for pediatric trials137

The approval of novel anti-cancer drugs for pediatric patients 138usually occurs after their approval for treating adult cancers. 139An ongoing challenge today is to define which agents in de-140velopment for treating adult cancers have potential therapeutic 141value for childhood cancers. On this basis, several plant-142derived compounds are currently successfully used in the 143treatment of different types of cancers in adult patients. 144Among these, various natural compounds are proposed as 145candidates for adjuvant treatment of childhood cancers 146(Table 2). 147

One of the most promising plant-derived chemopreventive 148agents is Ursolic acid, which is an ursane-type pentacyclic 149triterpenic acid that belongs to the cyclosqualenoid family of 150triterpenoids (Shanmugam et al. 2013). Ursolic acid has been 151reported in leaves and berries of several medicinal plants, 152including Arctostaphylos uva-ursi (L.) Spreng (bearberry), 153Vaccinium macrocarpon Air. (cranberry), Rhododendron 154hymenanthes Makino, Rosmarinus officinalis, Eriobotrya 155japonica, Calluna vulgaris, Ocimum sanctum, and Eugenia 156jambolana. Ursolic acid can have valuable effects in a variety 157of human diseases, including inflammation-driven cancers 158(Shanmugam et al. 2013), and it is well tolerated by adult 159patients with advanced tumors (Zhu et al. 2013). Therefore, 160the idea that Ursolic acid could become a powerful chemopre-161ventive agent in childhood tumors has been developed. Its 162molecular mechanisms have been studied in hepatoblastoma 163(Son et al. 2013) because of its pro-apoptotic effects in HepG2 164cells (Satomi et al. 2005) and in doxorubicin-resistant HepG2 165cells (Yang et al. 2010). The HepG2 cell line has for several 166years been confused in the literature, with its use as a model of 167

t2.1 **Table 2** Promising natural compounds for pediatric malignancies in clinic trials as anti-cancer agents in adult tumors. The main features of the natural compounds are given, with reference to their use in adult cancers

Compound	Molecular structure	Molecular formula	Molecular weight (g/mol)	Tumorigenic cells and/or mice models	Evidence in vitro and in vivo	Dose in vitro (µM)	Dose In vivo (mg/kg)	References
Ursolic acid		C ₃₀ H ₄₈ O ₃	456.70	Hepatoblastoma Leukemia	In vitro	20-30	-	(Yang, Liu et al. 2010) (Son, Kwon et al. 2013) (Deng, Zhang et al. 2014)
Triptolide		C ₂₀ H ₂₄ O ₆	360.40	Leukemia	In vitro	20-100	-	(Liu, Li et al. 2013) (Huang, Zhang et al. 2013)
Indirubin		C ₁₆ H ₁₀ N ₂ O ₂	262.26	Leukemia Glioblastoma	In vitro	10	-	(Nam, Scuto et al. 2012) (Williams, Nowicki et al. 2011)
Epothilone B	L'IL C	C ₂₇ H ₄₁ NO ₆ S	507.68	Neuroblastoma Rhabdomyosarcoma	In vitro and in vivo (animal models)	0.010- 0.100	1.5	(Scherzinger-Laude, Schonherr et al. 2013)
Tasidotin		^o C ₃₂ H ₅₈ N ₆ O ₅	606.84	Rhabdomyosarcoma Ewing's Sarcoma Synovial Sarcoma Osteosarcoma	In vitro and in vivo (animal models)	0.2-0.3	90	(Garg, Zhang et al. 2007)
Salinosporamid A	With the second	C ₁₅ H ₂₀ CINO ₄	313.77	Leukemia	In vitro	0.0051	-	(Ruiz, Krupnik et al. 2006) (Niewerth, Jansen et al. 2014)

168hepatocellular carcinoma, which is indeed a rare tumor in adults (Aden et al. 1979). Instead, recent studies of compara-169tive genomic hybridization and histopathology analyses 170 171(Lopez-Terrada et al. 2009) have shown that these cells are 172indeed epithelia hepatoblastoma, which mainly occurs during the early years of life, in children. Son et al. showed that the 173174Ursolic acid-induced apoptosis in HepG2 cells occurs in a caspase-dependent manner and is regulated by GSK3-β 175(Son et al. 2013). Their study revealed that in Ursolic acid-176177treated cells, there was a dose-dependent increase in the inhi-178bition of phosphorylation of GSK3- β (on serine 9), which 179blocked the up-regulation of the pro-apoptotic protein poly 180(ADP-ribose) polymerase (Son et al. 2013). Furthermore, these data also showed that this apoptosis was regulated by 181 Ursolic acid through the GSK3- β /AKT/mTOR axis, because 182183 Ursolic acid not only increased the phosphorylation of GSK3-ß but also down-regulated the Akt/mTOR signaling 184pathway (Son et al. 2013). Ursolic acid has recently been 185186 shown to also induce differentiation in the U937 leukemia cell line, with an increase in the levels of specific monocyte sur-187face markers (i.e., CD14, CD11b) through the activation of the 188 PI3K/Akt pathway (Deng et al. 2014). Moreover, Ursolic acid 189was less toxic than all-trans retinoic acid, which has already 190been successfully used as a therapy for acute promyelocytic 191leukemia (Johnson and Redner 2015). However, the 192193differentiation-inducing effects of all-trans retinoic acid are more efficient than those of Ursolic acid (Deng et al. 2014). 194Future studies need to determine the exact mechanism of 195

Ursolic acid-induced differentiation to promote the develop-
ment of new pharmacological drugs with higher therapeutic196197197effects and lower side effects for the treatment of leukemias198(Deng et al. 2014). Thus, in conclusion, Ursolic acid repre-
sents a potential candidate in the treatment of hepatoblastoma
and leukemia in children through its targeting of apoptosis and
induction of cell differentiation processes.201

A novel therapeutic strategy to treat hematological malig-203nancies is seen for the diterpene triepoxide Triptolide, which is 204the major active component in extracts from Triptervgium 205wilfordii Hook F. Triptolide has different pharmacological 206functions, which include anti-tumorigenic effects both 207in vitro and in vivo through down-regulation of anti-208apoptotic proteins (i.e., XIAP, Mcl-1) and up-regulation of 209pro-apoptotic proteins (i.e., p53, p21, Bax) (Liu et al. 2013). 210The roles of Triptolide in human leukemia cell lines and in 211primary human leukemia blasts have been investigated recent-212ly (Liu et al. 2013). These data show selective induction of 213caspase-dependent cell death and activation of Rho-associated 214coiled-coil-containing protein kinase ROCK1, which is re-215sponsible for stabilizing actin microfilaments and promoting 216217cell contraction and cell substratum contact (Liu et al. 2013). Triptolide has also been demonstrated to induce apoptosis in 218acute lymphoblastic leukemia cells that overexpress the 219MDM2 oncoprotein, through inhibition of MDM2 and XIAP 220expression (Huang et al. 2013). 221

Indirubin is another promising natural therapeutic agent 222 for hematological malignancies, and it has already been 223

Naunyn-Schmiedeberg's Arch Pharmacol

224used for the treatment of chronic myeloid leukemia (Xiao et al. 2002). It is an ingredient of the traditional Chinese 225herbal medicine "Danggui Longhui Wan" which is made 226 227 from 11 herbal ingredients (Xiao et al. 2002). Indirubin 228 has been shown to inhibit cell growth via the cyclin-229 dependent kinases (CDKs) in several human cancer cells, by targeting CDK1/cyclin B, CDK2/cyclin A, 230 CDK2/cyclin E, GSK3-\beta, and CDK5/p25 (Nam et al. 2312013). Indirubin derivatives have been demonstrated to 232inhibit the Signal Transducer and Activator of Transcrip-233tion member 5 (Stat-5) protein and to down-regulate the 234235expression of its target proteins Bcl-xL and Mcl-1, which are associated with induction of apoptosis (Nam et al. 2362012). This was shown in human K562 chronic myeloid 237leukemia cells, in imatinib-resistant human KCL-22 chron-238ic myeloid leukemia cells expressing the T315I mutant 239Bcr-Abl (KCL-22 M), and in CD34-positive primary 240chronic myeloid leukemia cells from patients (Nam et al. 2412012). Therefore, Indirubin derivatives represent a promis-242ing structural class for the development of new drugs for 243patients with wild-type or T315I mutant Bcr-Abl-positive 244chronic myeloid leukemia. Indirubin derivatives might also 245246 be useful for the treatment of pediatric solid tumors, because it can reduce the invasion of glioma cells and 247glioma-initiating cell-enriched neurospheres both in vitro 248249(by modulating β -catenin levels) and in vivo (by improving survival in glioma-bearing mice) (Williams et al. 2502011). These data suggest that Indirubin offers a novel 251252therapeutic approach that might well be applicable not only in pediatric hematological malignancies. 253

Natural compounds from microorganisms applied to adult clinical cancer trials that are of interest for pediatric trials

Microorganisms represent an attractive and advantageous source for the production of medically useful metabolites. In contrast to plants, they can be grown in culture media on a large scale, which provides an unlimited and uninterrupted supply of the raw material needed for drug development. Several anti-tumorigenic natural compounds have been derived from microorganisms.

Epothilones were discovered as secondary macrolide me-264265tabolites that are produced by the myxobacterium Sorangium cellulosum (Molnar et al. 2000). Like taxanes, epothilones are 266responsible for microtubule stabilization in vitro (Molnar et al. 2672000). Patupilone, which is also known as Epothilone B, is a 268potent microtubule stabilizer that belongs to this class (Molnar 269et al. 2000). Patupilone binds to β -tubulin with a higher affin-270ity than taxanes and alters their spindle formation, which re-271272sults in the arrest of mitotic cells, and cell death through apoptosis (Molnar et al. 2000). In comparison with taxanes, 273274Patupilone has been shown to be more potent in its in vivo anti-cancer activity at tolerated dose levels in two pediatric275tumor mice models of neuroblastoma and rhabdomyosarcoma276(Scherzinger-Laude et al. 2013).277

Additionally, a liposomal formulation of Patupilone was 278developed and characterized in both in vitro and in vivo 279studies (Scherzinger-Laude et al. 2013). Patupilone has 280been shown to have a strong anti-tumor effect in both of 281these pediatric cancer models, without triggering major 282side effects. These effects were not seen when Patupilone 283was delivered to integrin-expressing cells using RGD lipo-284somes. Moreover, tumor targeting of liposomal Patupilone 285enhances its anti-tumor activity in rhabdomyosarcoma 286(Scherzinger-Laude et al. 2013). The potent anti-tumor ef-287 fects and the significantly increasing cumulative survival 288of low-dose Patupilone-RGD-liposomes open the way to 289new pharmacological opportunities for targeting liposomes 290 as part of low-dose therapeutics in pediatric oncology. 291

Natural compounds from marine organisms applied292to adult clinical cancer trials that are of interest293for pediatric trials294

Marine organisms are another great source of secondary me-
tabolites. In the near future, the exploration of marine envi-
ronments will provide new potential natural compounds. To
297
date, the new classes of anti-cancer drugs isolated from marine
organisms have been shown to have cytotoxic activities
299
against multiple tumor types by targeting different signaling
300
pathways.

The progression of cell growth is inhibited by 302 dolastatins, which were originally identified in the Indian 303 Ocean sea hare Dolabella auricularia (Garg et al. 2007). 304 These are a group of proteins that can inhibit the assembly 305 of new microtubules by binding to tubulin and subsequent-306 ly inhibiting tubulin-dependent GTP hydrolysis in vitro 307 (Garg et al. 2007). Tasidotin HCl (also known as 308 ILX651) is a synthetic pentapeptide (i.e., N,N-dimethyl-309 L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-Lproline-tert-310 butylamide hydrochloride) (Garg et al. 2007). When ad-311ministered both orally and i.v., Tasidotin has shown strong 312activity in xenograft mice models of breast and ovarian 313 cancer, taxane-resistant ovarian cancer, prostate carcino-314mas, melanoma, non-small cell lung carcinoma, colon car-315cinoma, and P388 murine leukemia (Mita et al. 2006). 316 Several phase I multi-institution clinical trials of Tasidotin 317have recently been completed in adults (Mita et al. 2006), 318 although Tasidotin has not yet been explored for the treat-319ment of pediatric malignancies. With its promising anti-320 neoplastic activity, metabolic stability, and oral bioavail-321ability, Tasidotin shows potential for broad therapeutic ap-322 plications. Garg et al. investigated the effects of Tasidotin 323 in xenograft mice models of pediatric tumors (e.g., rhab-324 domyosarcoma, Ewing's sarcoma, synovial sarcoma, 325

osteosarcoma) (Garg et al. 2007). Here, Tasidotin showed
significant anti-tumoral activity in all of these mice xenograft model studies. These data demonstrate that Tasidotin
might have positive effects in the treatment of pediatric
sarcomas (Garg et al. 2007).

The effects of marine anti-tumorigenic agents have also 331 332 been tested in other pediatric tumor models, including 333 acute myeloid leukemia, acute lymphoblastic leukemia, and glioma (Potts et al. 2011). Salinosporamide A 334 335(Marizomib) is a natural β -lactone- γ -lactam proteasome inhibitor that was derived from the marine actinobacterium 336 337 Salinispora tropica (Potts et al. 2011). The proteasome represents an important clinical target for the treatment 338 of malignancies, and Marizomib has high specificity for 339 the proteasome by binding and inhibiting all three proteo-340 lytic protein subunits (i.e., $\beta 1$, $\beta 2$, $\beta 5$) (Potts et al. 2011). 341 A decade ago, the reversible proteasome inhibitor 342 Bortezomib was approved for the treatment of relapsed/ 343 344 refractory and newly diagnosed multiple myeloma and mantle cell lymphoma (Kane et al. 2006), and it represents 345an emerging treatment strategy for acute leukemia 346 (Messinger et al. 2012, Niewerth et al. 2013). The relevant 347 348 clinical disadvantages of Bortezomib are related to its unsuitability for oral administration, its toxicity profile, and 349the emergence of drug resistance (Kale and Moore 2012). 350 351Enhanced potency of Salinosporamide A over Bortezomib has been shown in human multiple myeloma cell lines 352(Chauhan et al. 2005) and in specimens from patients with 353 354chronic lymphocytic leukemia (Ruiz et al. 2006). 355Salinosporamide A might be attractive as a proteasome inhibitor in several malignancies, including acute leukemia. 356357 Indeed, tumor cell growth inhibition by Salinosporamide A has been evaluated in human CCRF-CEM acute lym-358 phocytic leukemia cells and in two of the Bortezomib-359 360 resistant sub-lines, CEM/BTZ7 (10-fold resistance to bortezomib) and CEM/BTZ200 (123-fold resistance to 361 362 Bortezomib) (Niewerth et al. 2014). These findings show 363 that Salinosporamide A is emerging as a potent antileukemic agent for both parental and bortezomib-resistant 364 leukemia cells. At this time, further clinical evaluations of 365 its suitability are required. 366

367 Novel promising plant-derived compounds for pediatric368 cancer treatment

369 To reduce toxicity and side effects due to current chemotherapeutic regimens, an increasing number of additional nature-370 derived molecules are currently under investigation to treat 371pediatric tumors (Table 3). Previously, we highlighted the im-372portance of medicinal plants, which have often been investi-373 374gated as sources of new drugs for treating cancer. Due of their low toxicity, plant-derived compounds can effectively reduce 375376 the toxicity that is often encountered in vivo.

Terminalia chebula is a member of the Combretaceae fam-377 ily that is native to India, and it is already being used in alter-378 native medicine (Kumar et al. 2014). One of its major com-379 ponents is the benzopyran tannin Chebulagic acid, the anti-380 tumor effects, and molecular mechanisms of which were stud-381 ied by Kumar et al. in retinoblastoma cells (Kumar et al. 382 2014). In recent years, a dramatic change in the management 383 of retinoblastoma has occurred, and several methods have 384now been developed, including focal (e.g., cryotherapy, laser 385 photocoagulation, transpupillary thermotherapy, plaque 386 brachytherapy), local (e.g., external beam radiotherapy, enu-387 cleation), and systemic (e.g., chemotherapy) methods (Pandey 388 2014). All of these can lead to terrible complications that can 389 include serious detachment, tearing, holding, traction and vas-390 cular retinal occlusion, and focal paraxial lens opacity (Pandey 391 2014). Primary enucleation and chemoreduction have become 392 the standard care for advanced intraocular retinoblastoma. 393 Chebulagic acid treatment decreases the proliferation of Y79 394 cells in a dose-dependent manner (Kumar et al. 2014). The 395 treated cells underwent apoptosis through increased expres-396 sion of BAX, decreased expression of Bcl2, release of cyto-397 chrome c, and activation of caspase 3 (Kumar et al. 2014). 398 Moreover, Chebulagic acid also induced G1 arrest through 399 induction of p27 expression and interference with the NFKB 400 pathway (Kumar et al. 2014). Chebulagic acid can also exert 401 in vitro angiogenic effects by decreasing cell sprouting in the 402 treated rat aortic ring and down-regulation of VEGF produc-403 tion and expression of endothelial specific markers (i.e., 404 CD31, E-selectin) (Athira et al. 2013). Further studies will 405 be required to determine the efficacy of Chebulagic acid in 406 children affected by retinoblastoma and to investigate its 407 in vivo anti-tumorigenic effects. 408

Among the emerging natural compounds, the naturally oc-409curring plant flavone (4',5,7-trihydroxyflavone), or Apigenin, 410 has been increasingly recognized as a cancer chemopreventive 411 agent because of its remarkable anti-mutagenic, anti-inflam-412matory, anti-oxidant, and anti-carcinogenic properties (Birt 413 et al. 2001). Apigenin is abundant in common fruit and veg-414 etables, including parsley, onions, oranges, tea, chamomile, 415wheat sprouts, and some seasonings (Birt et al. 2001). Several 416 studies have reported that Apigenin can induce apoptosis in a 417 wide range of tumor cells, including those derived from pedi-418atric tumors (e.g., leukemia and neuroblastoma cells), through 419 different cell signaling and transduction pathways, like NFkB, 420 p53, MAPK, and PI3K/Akt (Patel et al. 2007). Wang et al. 421demonstrated that Apigenin has the highest potency among all 422 of the flavonoids they tested for the induction of apoptosis in a 423 caspase-dependent manner in HL60 leukemia cells (Wang 424et al. 1999). Subsequently, Budhraja et al. showed that 425Apigenin can induce apoptosis in dose-dependent and time-426 dependent manners in U937 cells (Budhraja et al. 2012). Their 427 results suggest a hierarchical model of Apigenin-induced ap-428 optosis in human leukemia cells in which Akt inactivation 429

Naunyn-Schmiedeberg's Arch Pharmacol

t3.1 **Table 3** Novel natural compounds that can affect several tumorigenic pathways in vitro and/or in vitro in pediatric cancer models. The main features related to the natural compounds are given, as described in the text, for the promising anti-cancer drugs in pediatric tumors

Compound	Molecular structure	Molecular formula	Molecular weight (g/mol)	Tumorigenic cells and/or mice models	Evidence in vitro and in vivo	Dose in vitro (µM)	Dose in vivo (mg/kg)	References
Chebulic acid		C ₁₄ H ₁₂ O ₁₁	356.23	Retinoblastoma	In vitro	50	-	(Kumar, Gangappa et al. 2014)
Apigenin		$C_{15}H_{10}O_5$	270.23	Leukemia Neuroblastoma	In vitro and in vivo (animal models)	40-60	20-40	(Torkin, Lavoie et al. 2005) (Budhraja, Gao et al. 2012)
Norcantharidin		C ₈ H ₈ O ₄	168.15	Medulloblastoma Glioblastoma Leukemia Hepatoblastoma	In vitro and in vivo (animal models)	25-100	1-10	(Cimmino, Scoppettuolo et al. 2012) (Zheng, Du et al. 2014) (Liao, Chen et al. 2011) (Lu, Gao et al. 2014)
Crocin		° ° °	976.96	Hepatoblastoma Leukemia	In vitro and in vivo (animal models)	600-5000	6.25-25	(Noureini and Wink 2012) (Sun, Xu et al. 2013)
Parthenolide	0=0	$C_{15}H_{20}O_3$	248.32	Hepatoblastoma Glioblastoma	In vitro and	5-10	10-40	(Sun, Zhang et al. 2014) (Nakabayashi and Shimizu 2012)
				Leukemia Osteosarcoma	<i>in vivo</i> (animal models)			(Guzman, Rossi et al. 2005) (Diamanti, Cox et al. 2013) (Kishida, Yoshikawa et al. 2007)
Longikaurin E	O O O O O O O O O O O O O O O O O O O	$C_{22}H_{30}O_{6}$	390.47	Pancreatic tumor	In vitro	0,5-4	_	(Cheng, Bo et al. 2015)
Lupeol		C ₃₀ H ₅₀ O	426.73	Pancreatic tumor Osteosarcoma	In vitro and in vivo (animal models)	7.5-120	30-60	(Liu, Bi et al. 2015) (Liu, Bi et al. 2015)
Okadaic acid		C ₄₄ S ₆₈ O ₁₃	805	Retinoblastoma Neuroblastoma	In vitro	0.005-0.050	-	(Di Fiore, Drago-Ferrante et al. 2013) (Edelstein and Rockwell 2012)
Spongistatin 1		C ₆₅ H99ClO ₂₀	1235.92	Leukemia	In vitro	0.0002- 0.001	-	(Schyschka, Rudy et al. 2008)
Variolin b	$\begin{matrix} H_{2}N\\ N\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	$C_{14}H_{11}N_7O$	29328	Leukemia	In vitro	0.050-0.10	-	(Simone, Erba et al. 2005)

causes activation of JNK signaling, down-regulation of Mcl-1
and Bcl-2, and caspase activation (Budhraja et al. 2012). Furthermore, they also demonstrated that this flavonoid can inhibit tumor growth in vivo, in a U937 cell mice xenograft
model (Budhraja et al. 2012). However, the Akt and JNK
signaling pathways are not the only targets for Apigenin, because Arango et al. identified other 160 potential targets of

Apigenin using a phage display system coupled with second437generation sequencing, an innovative approach that provides438high-throughput discovery of small molecule–protein interac-439tions (Arango et al. 2013). They focused on heterogeneous440nuclear ribonucleoprotein A2 (hnRNPA2), which is an impor-441tant factor in the progression of tumorigenesis through the442regulation of splicing, messenger RNA (mRNA) stability,443Q24

AUTHOR'S-PROOT!

444 and mRNA transport (Arango et al. 2013). High expression of hnRNPA2/B1 has been reported in a variety of human cancers 445(Zhou et al. 2001), including glioblastoma (Golan-Gerstl et al. 446 447 2011). Arango et al. established that by interacting with the C-448 terminal domain of hnRNPA2, Apigenin inhibits hnRNPA2 dimerization and alters the alternative splicing patterns of the 449450hnRNPA2 substrates in breast cancer cells (Arango et al. 2013). Indeed, the addition of Apigenin to malignant cells 451reverts the splicing of caspase-9 and cellular FADD-like IL-4524531β-converting enzyme (FLICE)-inhibitory protein (c-FLIP), 454which are two key regulators of apoptosis, without acting against the splice variants in non-carcinogenic cells (Safa 4554562012). These results might help to explain how Apigenin 457 has an anti-carcinogenic activity by decreasing the inhibition of apoptosis (Arango et al. 2013). The effects of Apigenin 458459have also been studied in human neuroblastoma cells. Torkin et al. reported that Apigenin inhibits tumor growth and in-460 461 duces caspase-dependent apoptosis not only in vitro but also 462in a non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse xenograft model, using NUB-7 im-463 planted tumors (Torkin et al. 2005). Apigenin induced p53 464nuclear accumulation, thus leading to increased expression 465 466 of its target proteins (i.e., p21, Bax) (Torkin et al. 2005). Due to its apoptotic effect being restricted to tumorigenic cells 467 without toxicity shown to non-transformed neuronal cells, 468 469Apigenin emerged in this study as a potential compound for further development as a therapeutic agent for patients with 470471 neuroblastoma.

472Cantharidin is a natural compound that was originally iso-473 lated from beetles, and it is one of the most emergent antitumorigenic agents because of its broad therapeutic applica-474475tions across a large number of pediatric tumors (Torbeck et al. 2014). The clinical use of Cantharidin has, however, been lim-476 477 ited, because of its severe side effects, with analogs of Canthar-478idin synthesized to reduce this toxicity. Cantharidin and its 479 derivatives have been shown to have strong in vitro antitumor activities. Norcantharidin is a demethylated form of Can-480 481 tharidin, and it has already been used as a routine anti-cancer 482drug in China (Chen et al. 2005). Norcantharidin showed lower 483 toxicity toward normal cells and was more effective in anti-484 cancer activities (Chen et al. 2005, Liao et al. 2007). Canthar-485idin and Norcantharidin express their anti-cancer activities through inhibition of protein phosphatase 1 (PP1) and PP2A, 486 487 which are involved in cell-cycle progression. Norcantharidin is active in vitro against several tumor cell lines, including hepa-488 toma and leukemia cell lines, and its cytotoxic action has been 489demonstrated to be approximately 10-fold less than that of 490 Cantharidin in many of these cell lines (Tarleton et al. 2012). 491Norcantharidin has also shown potent anti-metastatic and anti-492angiogenic effects through inhibition of cell migration and 493494capillary-like tube formation in HUVEC cells, by decreasing 495the amount of pro-angiogenic secreted soluble factors (e.g., angiogenin, GRO, IGF-1, IL-8, MCP-1, VEGF), and without 496

significant toxicity (Chen et al. 2009). This inhibition was ac-497 companied by anoikis, down-regulation of integrin β 1, and 498breakdown of vimentin (Chen et al. 2009). Moreover, in vivo 499 experiments have demonstrated that Norcantharidin prolonged 500the survival and reduced the plasma VEGF levels in mice with 501 pulmonary metastasis without showing significant renal and 502 liver toxicity (Chen et al. 2009). Therefore, with its ability to 503 pass through the blood-brain barrier, Norcantharidin has been 504investigated for pediatric brain tumors in vitro and in vivo. In 505medulloblastoma cell lines, Norcantharidin treatment impaired 506the growth of DAOY and UW228 cells by affecting Wnt/β-507catenin signaling through nuclear *β*-catenin loss (Cimmino 508 et al. 2012). The efficacy of Norcantharidin to decrease medul-509loblastoma tumor growth was also assessed in vivo using me-510dulloblastoma orthotopic brain-cerebellum xenograft animal 511models. These results showed significantly reduced tumor size 512in the treated mice (Cimmino et al. 2012). Norcantharidin also 513inhibited cell growth by impairment of the Raf/MEK/ERK 514pathway in a dose-dependent manner, and it induced apoptosis 515in glioma cells through down-regulation of the pro-apoptotic 516proteins Bcl-2 and Mcl-1 (Zheng et al. 2014). Liao et al. devel-517oped a model to induce cancer progression via PMAI in a 518human T cell leukemia cell line and then defined the mecha-519nisms behind Norcantharidin for the inhibition of cell growth 520and induction of cell-cycle arrest (Liao et al. 2011). The results 521of this study showed that Norcantharidin can significantly in-522hibit the viability of these treated cells by induction of cell-cycle 523arrest at the G2/M phase, down-regulation of the expression of 524calcineurin, and attenuation of interleukin (IL)-2 production 525(Liao et al. 2011). These results provide important information 526 about the possible use of Norcantharidin as a chemopreventive 527agent to inhibit leukemia progression (Liao et al. 2011). Re-528cently, Norcantharidin was shown to have anti-tumor activity 529also through modulation of the tumor microenvironment in 530hepatocellular carcinoma models (Lu et al. 2014). Macro-531phages are known to take part in the tumor microenvironment 532and to have a dual role in tumor development and progression 533 (Lamagna et al. 2006). Classically, activated M1 macrophages 534have anti-tumor effects through the release of pro-inflammatory 535cytokines. On the contrary, alternatively activated M2 macro-536phages facilitate the progression of tumors, through the release 537 of anti-inflammatory cytokines (Sica et al. 2008). As a result, 538tumor-associated macrophages have been the target for cancer 539treatments. Norcantharidin inhibited tumor growth in 540 hepatoma-bearing mice through the β-catenin signaling path-541way and subsequently by shifting from M2 macrophage to M1 542macrophage polarization (Lu et al. 2014). 543

In hepatoblastoma, in addition to Norcantharidin, the antitumorigenic effects of *Crocus sativus* L. which is commonly known as Saffron have been investigated. This natural compound comes from this perennial stem-less herb of the large *Iridaceae* family that has been widely studied over the last decade for its biomedical properties (Abdullaev et al. 2003). 549

Naunyn-Schmiedeberg's Arch Pharmacol

550Chemopreventive potential of Saffron against cancer and the absence of toxicity and mutagenicity have been reported. In-551deed, Saffron appears to have cytotoxic activity against differ-552553ent tumorigenic cells, while no inhibitory effects are seen on normal cell growth (Abdullaev et al. 2003). Crocin is the main 554water-soluble carotenoid of Saffron extracts, and it represents 555556the most promising Saffron constituent as a therapeutic agent against cancers (Escribano et al. 1996). One of its anti-557tumorigenic effects relates to telomerase activity. In 558hepatoblastoma cell lines, Crocin has been shown to decrease 559telomerase activity by down-regulation of the expression of 560561hTERT, the catalytic subunit of telomerase (Noureini and Wink 2012). As the telomerase activity is high in cancer cells 562and almost undetectable in normal cells, it might be a selective 563 target in pediatric cancer therapy. Inhibition of telomerase 564would selectively suppress tumor growth without large effects 565on normal cells. Crocin anti-tumor effects have also been in-566567 vestigated in human leukemia cells, both in vitro and in vivo. 568HL-60 leukemia cells treated with Crocin showed a reduced proliferation rate and induction of apoptosis (Sun et al. 2013). 569Moreover, daily intraperitoneal injections of Crocin inhibited 570the growth of leukemia cells in nude mice through modulation 571572of the expression of the apoptosis-related molecules Bcl-2 and Bax (Sun et al. 2013). These findings suggested a potential 573574role for Crocin in the treatment of leukemia.

575Parthenolide is another promising plant-derived candidate for cancer chemoprevention. This is a sesquiterpene lactone 576that was originally purified from the shoots of the feverfew, 577 578 Tanacetum parthenium (Ghantous et al. 2013), that has shown 579 anti-cancer and anti-inflammatory activities in several cell lines derived from pediatric tumors (Gach et al. 2015). These 580581biological properties of Parthenolide can be attributed to its strong inhibition of NF κ B (Bork et al. 1997). It was also 582shown recently that Parthenolide can induce growth inhibi-583tion, autophagy, and caspase-mediated cell death in 584hepatoblastoma cells (Sun et al. 2014). Further, Parthenolide 585has been shown to suppress cell proliferation and invasion, 586587and tumor-induced angiogenesis in vitro, and to inhibit neovascularity and tumor growth in vivo in glioblastoma mice 588models (Nakabayashi and Shimizu 2012). It has been sug-589590 gested that this anti-tumor function of Parthenolide might be mediated not only by inhibition of NFkB but also by inhibi-591tion of Akt signaling (Nakabayashi and Shimizu 2012). It is of 592593note that Parthenolide effectively eradicated acute myeloid leukemia stem cells and progenitor cells in vitro while sparing 594normal hematopoietic stem cells (Guzman et al. 2005). Thus, 595596Parthenolide has been investigated as a potential chemotherapeutic agent in acute myeloid leukemia and acute B-597lymphoblastic leukemia cells (Guzman et al. 2005). Treat-598ments for pediatric patients with leukemia are now increasing-599600 ly successful. However, approximately 20 % of children with acute lymphoblastic leukemia relapse because of the failure to 601 eradicate the disease, and most of these patients do not 602

survive. Parthenolide was reported for the first time to eradi-603 cate multiple leukemia-initiating cell populations in vivo in 604 childhood acute lymphoblastic leukemia (Diamanti et al. 605 2013). For this reason, Parthenolide might have therapeutic 606 potential in childhood acute lymphoblastic leukemia, which 607 would provide a basis for the development of effective thera-608 pies that can eradicate leukemia-initiating cell populations, to 609 prevent disease progression and reduce relapse (Diamanti 610 et al. 2013). Osteosarcoma is a highly aggressive primary 611 bone tumor that predominantly affects children and typically 612 demonstrates significant resistance to radiotherapy (Fuchs and 613 Pritchard 2002). Consequently, the conventional treatments 614 do not prevent metastatic progression in 30 to 40 % of patients 615(Lisle et al. 2008). To obtain more effective treatments, it 616 might be necessary to target the mechanisms used by osteo-617 sarcoma cells to acquire significant resistance to radiotherapy. 618 This radio-resistance in the SaOS2 osteosarcoma cell line has 619 been demonstrated to be subsequent to up-regulation of NFKB 620 (Eliseev et al. 2005). As Parthenolide affects NFKB (Kishida 621 et al. 2007), it can potentially provide a clinical method to 622 decrease NFkB in patients with osteosarcoma, which would 623 allow the radiation therapy to have an effective role in this 624 cancer treatment. The in vitro treatment of these re-625 sensitized cancer stem cells and the entire cell population with 626 radiotherapy has also been investigated in osteosarcoma. The 627 results have indicated that Parthenolide and ionizing radiation 628 act synergistically to induce cell death in LM7 osteosarcoma 629 cells (Zuch et al. 2012). When used together with the stan-630 dard therapeutic regimen, Parthenolide has been pro-631 posed to increase the sensitivity of these cancerous cells 632 to radiotherapy, to provide more complete eradication of 633 the malignant tissue. In conclusion, Parthenolide has 634 been identified as a new therapeutic agent for glioblas-635 toma, leukemia, and hepatoblastoma in children, al-636 though the promise that Parthenolide holds for therapy 637 is still limited. This is because of different factors, in-638 cluding its off-target effects and hydrophobicity, which 639 limits its solubility, and thus its oral bioavailability. In 640 the near future, new strategies will be implemented in-641 volving low pharmacological doses of Parthenolide ei-642 ther alone or in combination with other drugs, which 643 will define its anti-tumorigenic potential both in vitro 644 and in vivo. 645

Longikaurin E is a novel natural compound that is derived 646 from the herbal medicine Rabdosia longituba (Cheng et al. 647 2015), and that has shown anti-proliferative and pro-apoptotic 648 effects in pancreatic cancer cell lines (Cheng et al. 2015). 649 Pancreatic tumors are very rare at pediatric ages, and surgery 650 remains the keystone to treat this tumor in children, as in 651 adults (Dall'igna et al. 2010). Cheng et al. showed that 652 Longikaurin E induces apoptosis of pancreatic cancer cells 653 by up-regulation of Bax and down-regulation of Bcl-xL, 654Bcl-2, Survivin, and c-Myc (Cheng et al. 2015). They also 655

AUTHOR'S-PROOP!

656 reported increased p38 phosphorylation and inhibition of the PI3K/Akt pathway in the treated cells. Although the anti-657 tumorigenic effects of Longikaurin E were observed in pan-658 659 creatic cancer cell lines derived from adult tumors (i.e., 660 PANC1, ASPC-1, and BxPC-3 human pancreatic cancer cells), Longikaurin E has emerged as a new drug with poten-661 662 tial applications also for pancreatic cancer in children (Cheng et al. 2015). Further studies will be necessary to test its anti-663 cancer effects on primary pancreatic tumorigenic cells derived 664 from patients of pediatric ages before its clinical application. 665

In pancreatic cancer, in addition to Longikaurin E, the anti-666 667 tumorigenic effects of Lupeol, a dietary triterpene, have been investigated (Liu et al. 2015a, b). Lupeol is found in fruit (such **Q25** 668 as olives, mangos, strawberries, grapes, and figs), in vegeta-669 bles, and in medicinal plants (Chaturvedi et al. 2008). Liu 670 et al. showed that Lupeol has anti-proliferative and pro-671 672 apoptotic effects on pancreatic cancer both in vitro and in vivo (Liu et al. 2015a, b). Lupeol induced cell-cycle arrest 673 674 by up-regulation of p21 and p27 and down-regulation of cyclin D1. Interestingly, following Lupeol treatment in vivo, 675 they showed decreased tumor growth and down-regulation 676 of p-ERK and p-Akt in tumor tissues (Liu et al. 2015a, b). 677 678 Lupeol has also been reported to have anti-cancer efficacy against chemoresistant pancreatic cancer cells through modu-679 lation of TRAIL/cFLIP, both in vitro and in vivo in athymic 680 681 mice (Murtaza et al. 2009). The anti-cancer effects of Lupeol have also been investigated in osteosarcoma, where it induced 682 apoptosis and cell-cycle arrest of human osteosarcoma cells 683 by targeting the PI3K/Akt/mTOR pathway (Liu et al. 2015a, 684 b). Moreover, Lupeol administration in vivo decreased tumor 685 growth and had no effects on the function of the liver and 686 687 kidneys (Liu et al. 2015a, b). These data suggested a potential role for Lupeol in the treatment of pancreatic cancer and 688 689 osteosarcoma.

Novel promising marine compounds for pediatric cancertreatment

692 The development of marine natural compounds is progressing actively, with a significant number of anti-tumor compounds 693 that are entering preclinical studies and early clinical evalua-694 tion. About 3000 new compounds have been identified from 695 marine organisms due to advances in deep-sea collection and 696 697 "aquaculture" technology, which demonstrates that the sea represents a huge potential source for drug discovery (da 698 Rocha et al. 2001). 699

Several phytoplanktonic species accumulated by shellfish
are responsible for the production of Okadaic acid, a lipophilic
toxin that causes human diarrheic shellfish poisoning, which
although not lethal, causes gastrointestinal symptoms that include diarrhea (92 %), nausea (80 %), vomiting (79 %), abdominal pain (53 %), and chills (10 %) (Valdiglesias et al.
2013). These symptoms vary according to the dose of toxin

ingested. The minimum dose of Okadaic acid responsible for 707 this poisoning in human is about 40 mg (Valdiglesias et al. 708 2013). Several classes of protein serine/threonine phospha-709 tases that regulate cell growth, division, and death and main-710 tenance of the cytoskeletal structure are targets of this toxin. 711 Indeed, Okadaic acid might cause inhibition of protein phos-712 phatases, particularly PP1 and PP2A, but also other types, 713 including PP4, PP5, and PP2B (Louzao et al. 2005). The most 714reported cytotoxic effect of Okadaic acid is apoptosis induc-715tion, while it is known to cause growth inhibition and apopto-716sis and to induce oxidative stress in different cell types 717 (Valdiglesias et al. 2013). Nevertheless, the genotoxic and 718 cytotoxic effects caused by Okadaic acid might be responsible 719 for genomic instability that can lead to severe pathologies, 720 including cancer (Valdiglesias et al. 2013). Despite these cy-721totoxic and genotoxic effects, Okadaic acid might still repre-722 sent a novel candidate for neuroblastoma and retinoblastoma 723 treatment in children. Edelstein et al. showed that in neuro-724 blastoma cells, PPA2 inhibition by Okadaic acid induced Akt 725hyperphosphorylation, increased levels of ubiquitinated pro-726 teins, oxidative stress, loss of cell viability, and cell death 727 (Edelstein and Rockwell 2012). Furthermore, they demon-728strated that Rapamycin can enhance Okadaic acid-induced 729 Akt phosphorylation, to increase the susceptibility of cells to 730 pro-oxidant cell death caused by Okadaic acid (Edelstein and 731Rockwell 2012). The effects of Okadaic acid in combination 732 with Parthenolide were investigated in human retinoblastoma 733 cells (Di Fiore et al. 2013). These two compounds acted to-734 gether to induce cytotoxicity in Y79 cells by lowering p-Akt 735 levels, stabilizing p53, increasing reactive oxygen species, and 736 concurrently lowering glutathione content (Di Fiore et al. 737 2013). These results provide strong support for a combined 738 treatment approach to target the PTEN/Akt/mDM2/p53 path-739 way in this childhood tumor (Di Fiore et al. 2013). The mo-740 lecular effects of Okadaic acid appear to be cell-type depen-741 dent. Valdiglesias et al. showed that Okadaic acid can produce 742 oxidative DNA damage both in human peripheral leukocytes 743 and human neuroblastoma cells but not in human 744hepatoblastoma cells (Valdiglesias et al. 2011). They conclud-745ed that the mechanism leading to DNA damage is highly 746dependent on cell type. Other studies will be necessary to 747 identify the exact mechanisms of action of Okadaic acid in 748different tumorigenic cell lines. 749

Spongistatin 1 is a macrocyclic lactone that was isolated 750 from the marine sponges Spirastrella spinispirulifera and 751Hyrtios erecta as a cytotoxic antimitotic compound (Bai 752et al. 1993). It can block the cell cycle in the mitotic phase 753in L120 murine leukemia cells (Bai et al. 1993). Spongistatin 7541 has been shown to induce cell death in Jurkat leukemia T 755cells and, more importantly, in primary acute leukemic cells 756 derived from patients (Schyschka et al. 2008). Furthermore, 757 inhibitor-of-apoptosis proteins (IAPs) are overexpressed in 758cancer cells and in primary tumor biopsy samples (Salvesen 759

Naunyn-Schmiedeberg's Arch Pharmacol

760 and Duckett 2002). Drugs designed to specifically target these anti-apoptotic proteins might be valuable to overcome 761 762 chemoresistance. Of note, Spongistatin 1 can induce 763 protein degradation of the X-linked XIAP, thus 764 impairing the XIAP-overexpressing function in Jurkat cells, and therefore targeting an important molecular 765 key in the apoptosis resistance of tumorigenic cells 766 767 (Schyschka et al. 2008).

Variolin B is a novel marine natural product that was 768 isolated from the sponge Kirkpatrickia variolosa, which is 769found in Antarctica (Dembitsky et al. 2005). As it has 770 771 been shown to have pro-apoptotic activity, Variolin B represented a new potent natural cytotoxic agent (Dembitsky 772 et al. 2005). The use of Variolin B is limited by its low 773 stability in solution. However, the development of a 774 Deoxy-variolin B analog that is much more stable and 775 776 soluble has overcome this limitation of the parent compound (Anderson et al. 2005). The biological activity of 777 this deoxy analog was similar to that of Variolin B, with a 778 779 slight increase in potency of the deoxy analog that is likely to be related to its greater stability and solubility 780 (Anderson et al. 2005). The biological properties of 781 782 Variolin B and its deoxy analog, and their mechanisms of action, have been investigated in detail in several tu-783 morigenic cells, including the K562 human leukemic and 784 785 Jurkat cell lines (Simone et al. 2005). Both of these compounds inhibited colony formation and caused cell-cycle 786perturbations through increased p53 tumor suppressor 787 788 protein function and p21, thus definitively inducing apo-789 ptosis (Simone et al. 2005). However, the increase in p53 appears to be due to cellular stress induced by the dose of 790 791 the treatment and does not appear to be crucial for the biological effects of Variolin B and its deoxy analog. In-792 deed, there were no differences seen in vitro in comparing 793 794 the cytotoxicity combined with the cell-cycle perturbations induced by Variolin B and its deoxy analog in cell 795 796 lines expressing wild-type p53 and within sub-lines that had no p53 expression or contained an inactivated p53 797 isoform (Simone et al. 2005). Moreover, Variolin B and 798 its deoxy analog prevented the cells from entering S phase 799 by inhibition of the CDK1/cyclin B, CDK2/cyclin A, and 800 CDK2/cylin E complexes (Simone et al. 2005). In conclu-801 sion here, these Variolins can be considered as a new class 802 803 of CDK inhibitors that activate apoptosis in a p53independent manner, and thus they might be effective 804 against not only pediatric tumors but also several cancers 805 with p53 mutations or deletions. 806

Altogether, the data here reported support the idea that among marine and herbal-derived compounds, there is a variety of potentially effective anti-cancer agents that can act on several key targets of the tumorigenic processes. Future studies need to be performed soon to address their properties in vivo, to support new clinical trials in childhood cancers.

Nutraceutical and functional foods as anti-cancer drugs813to support pediatric cancer treatment814


Several natural compounds ingested in the diet are known to815have anti-tumorigenic effects. As many nutraceuticals and816functional foods have been demonstrated to have anti-cancer817actions, they might represent novel agents for the treatment of818pediatric cancers (Table 4).819Q26

Among the nutraceuticals, mushrooms contain a large820number of compounds that can target different pathways that821are responsible for cancer progression, which include those822that modulate the tumor microenvironment. Jiang et al. pro-823vided a complete list of mushrooms that have been shown to824target cancer cells and, in particular, tumorigenic cells derived825from pediatric tumors (Jiang et al. 2015).826

The Basidiomycete fungus Agaricus blazei Murill is an 827 edible mushroom that is cultivated in Japan, China, and 828 Brazil and belongs to the Agaricaceae family (Kim et al. 829 2009). It is already used in association with standard che-830 motherapeutics in Japan for cancer therapy (Yoshimura 831 et al. 2005). Extracts of A. blazei have shown inhibition 832 of cell growth and induction of apoptosis in several types 833 of tumorigenic cells. Its anti-proliferative effects are partly 834 mediated by apoptosis, as reported for different leukemic 835 cells, although not in normal cells, which has suggested a 836 tumor-selective action (Kim et al. 2009). These effects 837 have been confirmed in vivo, with inhibition of tumor 838 growth of human acute promyelocytic leukemia cells in 839 nude mice following administration of A. blazei extracts 840 (Kim et al. 2009). Later, Agaritine was discovered as one 841 of the A. blazei components responsible for these anti-842 leukemic properties (Akiyama et al. 2011). Agaritine puri-843 fied from A. blazei directly suppressed cell proliferation 844 through induction of apoptosis in several leukemic cell 845 lines and showed no effects on normal lymphatic cells 846 (Akiyama et al. 2011). However, Agaritine is not the only 847 interesting physicochemical agent in these A. blazei ex-848 tracts, with the demonstration of induction of caspase-849 dependent apoptosis in osteosarcoma cells using the poly-850 saccharide ABP-Ia from A. blazei (Wu et al. 2012). This 851study also showed no apoptotic effects for a normal hu-852 man osteoblast cell line, highlighting again the targeted 853 action of these agents toward tumorigenic cells (Wu 854 et al. 2012). The effects of A. blazei extracts on sarcoma 855 have been investigated in vivo using the α -(1-4)-856 glucan- β -(1-6)-glucan-protein complex polysaccharide 857 alone or in association with the chemotherapeutic agent 858 5-fluorouracil (Gonzaga et al. 2009). These data showed 859 strong inhibition of tumor growth and improvement of 860 survival in sarcoma-180-bearing mice, while no changes 861 were seen for the renal, liver, and hematological parame-862 ters, which indicated the absence of toxicological effects 863 in the treated mice (Gonzaga et al. 2009). Of note, the 864

AUTHOR'S-PROOT!

t4.1 **Table 4** Nutraceutical and functional foods that can affect several pathways in pediatric tumors. The main features of the nutraceuticals and functional foods described in the text are given



typical leukopenia due to the use of 5-fluorouracil was abrogated by the association with the polysaccharide derived from *A. blazei* (Gonzaga et al. 2009). It can be concluded that, together with this standard chemotherapeutic drug, this polysaccharide was not only responsible for the increment in the anti-tumor effects but also for the decrease in the side effects of the chemotherapy.

872 Another interesting mushroom with anti-cancer properties is Ganoderma sinensis, which is widely used in China as a 873 herbal medicine (Zhou et al. 2007). Among its components, 874 875 triterpenoid-enriched lipids have emerged due to their immunomodulatory and cytotoxic effects. Dose-dependent suppres-876 sion of proliferation of leukemia and hepatoblastoma cells has 877 878 been described for a lipid extract of this G. sinensis mushroom, known as GL6. Furthermore, the same GL6 was shown 879 to induce human monocytes and immunosuppressive M2 880 macrophages to release pro-inflammatory cytokines (Yue 881 882 et al. 2008). This feature makes this mushroom-derived com-883 pound a novel anti-cancer and immune-modulatory agent (Yue et al. 2008). However, careful clinical studies are still 884

required to determine whether these mushrooms do indeed 885 provide concrete benefits to patients, due to the toxicological 886 problems associated with their use. Additionally, in vivo data 887 will be necessary to investigate their molecular mechanisms 888 and their safety. 889

Another promising anti-tumorigenic natural compound is 890 contained in foods such as Garlic (Allium sativum), a bul-891 bous plant that is easy to grown in mild climates. Among its 892 components, Diallyl trisulfide and Ajoene are of importance 893 not only for their remarkable anti-tumor and cancer-894 preventive effects, as suggested by many in vitro and 895 in vivo studies, but also because of their many health ben-896 efits, like improvements to immune-system function, radio-897 protection, and protection against microbial infections 898 (BayanBayan et al. 2014). These features make them excel-899 lent candidates for the treatment of pediatric cancers. In-900 deed, Diallyl trisulfide has been demonstrated to arrest 901 HepG2 hepatoblastoma cell proliferation by inducing 902 caspase-3 activity, enhancing H₂O₂ levels, and strongly de-903 creasing glutathione levels (Iciek et al. 2012). Moreover, 904

Naunyn-Schmiedeberg's Arch Pharmacol

905 anti-cancer effects of Diallyl trisulfide have been shown in glioblastoma, with the reduction of cancer progression in 906 U87/MG ectopic tumors in SCID mice (Wallace, G. C. t 907 908 et al. 2013). As Diallyl trisulfide has not shown any nega-909 tive impact on hepatic functions, it can be considered an effective therapeutic agent for the prevention of tumor 910 progression in glioblastoma (Wallace, G. C. t et al. 911 2013). Instead, Ajoene has been shown not only to inhibit 912cell proliferation and induce caspase-dependent apoptosis 913 of several human myeloid leukemia cells but also to 914 strongly enhance the apoptotic effects of two chemothera-915916 peutic drugs: cytarabine and fludarabine (Hassan 2004). This was observed for the treatment of human CD34-917 positive resistant myeloid leukemia cells, through enhance-918 ment of their Bcl-2 inhibitory and caspase-3 activation 919 activities (Hassan 2004). Thus, these food-derived natural 920 921 compounds can be considered as potent agents with cancer-preventive properties. 922

One of the commonest popular beverages is green 923 tea. The correlation between its consumption and inhi-924 bition of the growth of a number of cancers is already 925 known (Kanadzu et al. 2006). Green tea contains at 926 927 least four catechins: epigallocatechin gallate (EGCG), epigallocatechin, epicatechin gallate, and epicatechin 928 (Kanadzu et al. 2006). The most abundant agent in 929 930 green tea is EGCG. Its anti-cancer effects have been investigated also in neuroblastoma. Tumor-initiating 931 cells were recently identified in neuroblastoma as 932 spheres grown in the serum-free nonadherent culture 933 934 used for neural-crest stem-cell growth. EGCG inhibited growth and induced apoptosis in BE(2)-C neuroblastoma 935 cells in a dose-dependent manner, although it did not 936 have the same biological effects against such spheres 937 derived from BE(2)-C cells (Nishimura et al. 2012). 938 However, EGCG inhibited the formation of these 939 spheres. So, it will be important to clarify the molecular 940 basis behind the EGCG-sensitive sphere formation in 941 neuroblastoma cells to determine its future clinical ap-942 plications in children with neuroblastoma (Nishimura 943 et al. 2012). Moreover, EGCG has also been demon-944 strated to inhibit hepatoblastoma cell growth in a time-945 dependent and dose-dependent manner while leaving 946normal fibroblasts unaffected (Godeke et al. 2013). 947 948 The treated hepatoblastoma cells showed impairment of the WNT signaling pathway (Godeke et al. 2013). This 949 is known to enhance cell proliferation, with subsequent 950 reduction in mRNA levels of its main target genes, c-951MYC and CCND1, together with re-expression of the 952tumor suppressor gene SFRP1, which is usually silenced 953 in these cells, thus impairing its known function: to 954955 down-regulate WNT signaling (Godeke et al. 2013). For these reasons, EGCG should be further investigated 956 for its potential clinical applications in the therapy of 957

hepatoblastoma, mainly because of its selective actions 958 toward tumorigenic cells. 959

Functional foods as anti-cancer drugs for pediatric cancer960treatment961

The available literature has emphasized the potential advan-962 tages of functional foods as chemopreventive agents, both 963 alone and in association with standard chemotherapeutics. 964 Several studies have focused on the anti-tumorigenic effects 965 of Curcumin (also known as Turmeric), a polyphenolic agent 966 derived from the Curcuma longa plant. This plant has been 967 used in Ayurvedic medicine for centuries because of its non-968 toxic effects and its therapeutic properties, which include anti-969 cancer activity (Villegas et al. 2011). Indeed, Curcumin has 970 been shown to have anti-proliferative effects in multiple can-971 cers, including pediatric tumors, through targeting several 972 pathways involved in tumorigenesis, including the MAPK, 973 PI3K, and NFKB signaling pathways, and impairing metasta-974 sis formation (Heger et al. 2014);(Villegas et al. 2011). One of 975 the most interesting features that makes Curcumin an ideal 976 compound to treat pediatric brain tumors is that it can cross 977 the blood-brain barrier due to its high lipophilic properties 978 (Marchiani et al. 2014). In addition, Curcumin has been 979 shown to induce apoptosis in vitro in human medulloblastoma 980 cells, and to reduce tumor growth, thus increasing survival 981 rates in vivo in mouse models of medulloblastoma, without 982 showing any toxic effects (Lee et al. 2011). Curcumin has 983 been shown to bind the phosphorylated form of the protein 984 Cdc27, and the data that have been reported indicate that due 985 to the phosphorylated Cdc27, the fast-growing medulloblas-986 toma cells were more susceptible to Curcumin-induced cell 987 death than those that only had non-phosphorylated Cdc27 988 (Lee and Langhans 2012). These results not only provided a 989 possible explanation for the selective mechanism of action of 990 Curcumin, but they also suggested that the phosphorylation 991 status of Cdc27 might be developed as a biomarker to predict 992 which patients might respond favorably to Curcumin-based 993 cancer therapy (Lee and Langhans 2012). Recently, the im-994 pairment of the Wnt/ β -catenin signaling pathway by 995 Curcumin in medulloblastoma cells was reported (He et al. 996 2014). In particular, this led to GSK-3ß activation and subse-997 quent nuclear β -catenin down-regulation (He et al. 2014). 998 Moreover, Curcumin anti-tumorigenic effects were also 999 shown in neuroblastoma cells (Picone et al. 2014). These 1000 treated cells showed a rapid increase in reactive oxygen spe-1001 cies, decrease in mitochondrial membrane potential, increase 1002 in the pro-apoptotic protein Bcl-2-associated death promoter 1003 (BAD), inhibition of Akt signaling, and activation of the pro-1004apoptotic proteins p27, Bim, and the Fas-L tumor necrosis 1005factor family protein (Picone et al. 2014). All of these events 1006 together suggest the induction of apoptosis in these neuroblas-1007 toma cells (Picone et al. 2014). Indeed, altogether, these 1008

results provide evidence for considering Curcumin as an idealtherapeutic agent for children with brain tumors.

Additional attention has been given to Resveratrol (i.e., 1011 1012 trans-3, 5, 40-trihydroxystilbene), which is a phytoalexin that 1013 is found in many plants, including those often consumed by human, such as grapes, peanuts, and berries (Carter et al. 10141015 2014). It is not only found in these plants but also in processed products from them, like wine (Carter et al. 2014). Several 1016 in vitro studies have shown that Resveratrol has multiple 1017 1018 anti-tumorigenic effects through the promotion of cell-cycle 1019 arrest and induction of apoptosis of tumorigenic cells, by in-1020 hibition of tumor growth and cell motility (Carter et al. 2014). The anti-leukemic effects of were reported by Ge et al., who Q27 1021 showed that Resveratrol induces cell-cycle arrest, apoptosis, 1022 and autophagy in acute T-lymphoblastic leukemia cells 1023 through inhibition of the Akt/mTOR/p70S6K/4E-BP1 path-1024 1025 way and activation of the p38-MAPK signaling pathway 1026 (Ge et al. 2013). Furthermore, the anti-tumor effects of Res-1027 veratrol have also been described in in vivo neuroblastoma studies (Soto et al. 2011). The combination of Resveratrol 1028

and immunocytokine regimens has been reported to enhance 1029anti-tumor activity and improve tumor-free survival in neuro-1030 blastoma mice models, while Resveratrol alone only induced 1031 tumor regression in primary sites. Indeed, the mice treated 1032with Resveratrol alone developed tumor recurrence and me-1033 tastasis (Soto et al. 2011). These results suggest a role for 1034 Resveratrol in the treatment of acute lymphoblastic leukemia 1035 and neuroblastoma. 1036

Finally, the flavonol Quercetin is an interesting natural 1037 compound that is contained in different types of fruit (e.g., 1038 apples, berries), vegetables (e.g., brassica, onion), black tea, 1039red wine, and many seeds, nuts, flowers, barks, and leaves 1040 (Sugantha Priya et al. 2014). As Quercetin has been shown 1041 to have many interesting biological properties, including as an 1042 anti-oxidant, anti-inflammatory, and anti-neoplastic, it appears 1043 to be a candidate for prevention and treatment of childhood 1044 tumors. Its anti-tumorigenic activity has been studied in neu-1045roblastoma cells (Sugantha Priya et al. 2014). Here, Quercetin 1046 was shown to retain its ability to induce caspase-dependent 1047 apoptosis in murine neuroblastoma neuro2a cell lines 1048




Fig. 1 Intracellular pathways altered by natural compounds in childhood malignancies. Illustration of the novel natural compounds that have been identified recently as having negative effects on intracellular signaling pathways involved in angiogenesis and metastasis formation in

pediatric tumors. The *colors of the arrows* represent the types of cancer (see color legend); *dashed lines* indicate those compounds identified from literature searches into nutraceuticals and functional foods

Naunyn-Schmiedeberg's Arch Pharmacol

1049 (Sugantha Priya et al. 2014). Further studies are required to1050 investigate the exact mechanism of Quercetin action, toward1051 the development of novel therapeutic approaches in neuro-

1052 blastoma treatment in vivo.

1053 Conclusions

1054 In recent years, great contributions to childhood cancer thera-1055py have been made through the use of natural compounds. 1056 Despite the technological progress in combinatorial chemistry, 1057 synthetic anti-cancer drugs continue to be responsible for non-1058selective killing of cells. As natural compounds have been 1059 shown to offer therapeutic actions with low cytotoxicity in several studies, and due to their chemical diversity, structural 1060 1061 complexity, and biological potency, they should be considered further as major sources of drug leads, especially for the treat-10621063 ment of childhood cancers. These compounds are still provid-1064 ing important impacts on drug discovery as they act as templates for the construction of novel nature-derived molecules, 1065with the challenge being to enhance the biological properties 10661067 and reduce the side effects.

1068 Despite recent progress in pediatric tumor treatment, cancer continues to be the major reason for childhood mortality, and 1069 conventional therapies are responsible for poor health-related 1070 1071 quality of life and chronic health conditions in childhood cancer survivors. Due to their potential to affect every tissue, 1072current non-selective therapies might have indeterminate 1073 1074long-term effects in young children. Thus, future studies should better identify and manage the functional outcomes 1075of childhood cancer survivors because of their emotional dis-10761077 tress (e.g., depressive symptoms, anxiety, increased somatization) and their reduced healthcare due to long-term side effects 1078 1079 of current therapies (Kinahan et al. 2012). Thus, natural compounds, including dietary factors, nutraceuticals, and especial-1080 ly functional foods (e.g., Quercetin, Resveratrol, EGCG, 1081 Diallyl trisulfide, Ajoene), are of significance here. As a result 10821083of their low toxicity and targeting of a wide range of signaling pathways involved in tumorigenesis, such natural compounds 10841085can be used to decrease these therapy-related side effects in 1086children (as shown in Fig. 1).

The introduction of such bioactive, nature-derived agents 1087 into clinics has changed the outcome of several types of pedi-1088 1089 atric cancers. Nevertheless, many efforts need to be focused on drug discovery of further new natural compounds, to iden-1090 tify new drugs derived from novel natural products. This will 1091 1092also increase their efficacy and reduce their side effects in children, with the need to also facilitate their handling and 1093 tolerability by developing oral regimens and/or liposomal for-1094mulation. Plants still represent a great source for natural com-10951096 pounds in drug discovery but microorganisms and marine-1097 derived compounds will have governing roles in the future, with a large number of promising molecules that are already 1098

undergoing clinical development as anti-cancer agents for 1099 childhood tumors. 1100

AcknowledgmentsThe authors thank Fondazione Adolfo Volpe e1101Associazione Pediatri di Famiglia, AIRC 2011–2014 MZ for grant support.1102port. We thank Dr. Pasqualino De Antonellis and Dr. MariaNeve1103Carotenuto of CEINGE, Naples, Italy, for critical comments on the manuscript. The authors dedicate this article to the work and passion of Dr.1105Roberta Migliorati (Hospital SantoBono-Pausillipon, Naples, Italy), a110611071108

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing 1110 interests. 1111

1112

1145

1146

1109

References

- 1113
- Abdullaev FI, Riveron-Negrete L, Caballero-Ortega H, Manuel 1115Hernandez J, Perez-Lopez I, Pereda-Miranda R, Espinosa-Aguirre 1116 JJ (2003) Use of in vitro assays to assess the potential antigenotoxic 1117 and cytotoxic effects of saffron (Crocus sativus L.). Toxicol In Vitro 1118 17(5-6):731-736 1119 Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB (1979) 1120 1121 Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282(5739):615-616 1122 Akiyama H, Endo M, Matsui T, Katsuda I, Emi N, Kawamoto Y, Koike T, 11231124
- Beppu H (2011) Agaritine from Agaricus blazei Murrill induces apoptosis in the leukemic cell line U937. Biochim Biophys Acta 1810(5):519–525 1126
- Anderson NE (2003) Late complications in childhood central nervous system tumour survivors. Curr Opin Neurol 16(6):677–683 1128
- Anderson RJ, Hill JB, Morris JC (2005) Concise total syntheses of 1129 variolin B and deoxyvariolin B. J Org Chem 70(16):6204–6212 1130
- Arango D, Morohashi K, Yilmaz A, Kuramochi K, Parihar A, Brahimaj
 B, Grotewold E, Doseff AI (2013) Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets. Proc Natl Acad Sci U S A 110(24):
 E2153–2162
- Athira AP, Helen A, Saja K, Reddanna P, Sudhakaran PR (2013)1136Inhibition of angiogenesis in vitro by chebulagic acid: a COX-
LOX dual inhibitor. Int J Vasc Med 2013:8438971137
- Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E (1993) Spongistatin11391, a highly cytotoxic, sponge-derived, marine natural product that
inhibits mitosis, microtubule assembly, and the binding of vinblas-
tine to tubulin. Mol Pharmacol 44(4):757–7661142
- Bayan L, Koulivand PH, Gorji A (2014) Garlic: a review of potential 1143 therapeutic effects. Avicenna J Phytomed 4(1):1–14 1144
- Birt DF, Hendrich S, Wang W (2001) Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90(2–3):157–177
- Bork PM, Schmitz ML, Kuhnt M, Escher C, Heinrich M (1997)1147Sesquiterpene lactone containing Mexican Indian medicinal plants1148and pure sesquiterpene lactones as potent inhibitors of transcription1149factor NF-kappaB. FEBS Lett 402(1):85–901150

Brydoy M, Fossa SD, Dahl O, Bjoro T (2007) Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 46(4):480–489 1152

- Budhraja A, Gao N, Zhang Z, Son YO, Cheng S, Wang X, Ding S, Hitron
 A, Chen G, Luo J, Shi X (2012) Apigenin induces apoptosis in
 human leukemia cells and exhibits anti-leukemic activity in vivo.
 Mol Cancer Ther 11(1):132–142
- Carter LG, D'Orazio JA, Pearson KJ (2014) Resveratrol and cancer: focus 1157 on in vivo evidence. Endocr Relat Cancer 21(3):R209–225 1158

AUTHOR'S-PROOT!

1159

1160

1161

- Chaturvedi PK, Bhui K, Shukla Y (2008) Lupeol: connotations for chemoprevention. Cancer Lett 263(1):1–13 Garg V, 2 Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M,
- 1162Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C,1163Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino1164MA, Anderson KC (2005) A novel orally active proteasome inhib-1165Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino
- 1165itor induces apoptosis in multiple myeloma cells with mechanisms1166distinct from Bortezomib. Cancer Cell 8(5):407–419
- 1167 Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, Liao HF (2005)
 1168 Inhibitory effect of norcantharidin, a derivative compound from
 1169 blister beetles, on tumor invasion and metastasis in CT26 colorectal
 1170 adenocarcinoma cells. Anti-Cancer Drugs 16(3):293–299
- 1171 Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF (2009)
 1172 Norcantharidin is a small-molecule synthetic compound with antiangiogenesis effect. Life Sci 85(17–18):642–651
- 1174 Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL (2015)
 1175 Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn
 1177 Schmiedeberg's Arch Pharmacol 388(6):623–634
- 1178 Cimmino F, Scoppettuolo MN, Carotenuto M, De Antonellis P, Dato VD,
- 1179De Vita G, Zollo M (2012) Norcantharidin impairs medulloblastoma1180growth by inhibition of Wnt/beta-catenin signaling. J Neurooncol1181106(1):59–70
- da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in
 anticancer therapy. Curr Opin Pharmacol 1(4):364–369
- 1184 Dall'igna P, Cecchetto G, Bisogno G, Conte M, Chiesa PL,
 1185 D'Angelo P, De Leonardis F, De Salvo G, Favini F, Ferrari
 1186 A, Group T (2010) "Pancreatic tumors in children and ado1187 lescents: the Italian TREP project experience.". Pediatr Blood
 1188 Cancer 54(5):675–680
- Q24189Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G,
Jonczyk A, Goodman SL, Kessler H (1999) N-Methylated cyclic1191RGD peptides as highly active and selective alpha(V)beta(3)1192integrin antagonists. J Med Chem 42(16):3033–3040
 - 1193Dembitsky VM, Gloriozova TA, Poroikov VV (2005) Novel antitumor1194agents: marine sponge alkaloids, their synthetic analogs and deriva-1195tives. Mini-Rev Med Chem 5(3):319–336
 - 1196 Deng L, Zhang R, Tang F, Li C, Xing YY, Xi T (2014) Ursolic acid
 1197 induces U937 cells differentiation by PI3K/Akt pathway activation.
 1198 Chin J Nat Med 12(1):15–19
 - 1199 Di Fiore R, Drago-Ferrante R, D'Anneo A, Augello G, Carlisi D, De
 1200 Blasio A, Giuliano M, Tesoriere G, Vento R (2013) In human reti1201 noblastoma Y79 cells okadaic acid-parthenolide co-treatment in1202 duces synergistic apoptotic effects, with PTEN as a key player.
 1203 Cancer Biol Ther 14(10):922–931
 - 1204 Diamanti P, Cox CV, Moppett JP, Blair A (2013) Parthenolide eliminates
 1205 leukemia-initiating cell populations and improves survival in xeno1206 grafts of childhood acute lymphoblastic leukemia. Blood 121(8):
 1207 1384–1393
 - 1208Edelstein J, Rockwell P (2012) Okadaic acid induces Akt1209hyperphosphorylation and an oxidative stress-mediated cell death1210in serum starved SK-N-SH human neuroblastoma cells that are aug-1211mented by rapamycin. Neurosci Lett 531(2):74–79
 - 1212 Eliseev RA, Zuscik MJ, Schwarz EM, O'Keefe RJ, Drissi H, Rosier RN
 1213 (2005) Increased radiation-induced apoptosis of Saos2 cells via in1214 hibition of NFkappaB: a role for c-Jun N-terminal kinase. J Cell
 1215 Biochem 96(6):1262–1273
 - 1216Escribano J, Alonso GL, Coca-Prados M, Fernandez JA (1996) Crocin,1217safranal and picrocrocin from saffron (Crocus sativus L.) inhibit the1218growth of human cancer cells in vitro. Cancer Lett 100(1-2):23-30
 - 1219
 Fuchs B, Pritchard DJ (2002) Etiology of osteosarcoma. Clin Orthop

 1220
 Relat Res(397): 40–52
 - Gach K, Dlugosz A, Janecka A (2015) The role of oxidative stress in anticancer activity of sesquiterpene lactones. Naunyn Schmiedeberg's Arch Pharmacol 388(5):477–486

- Garg V, Zhang W, Gidwani P, Kim M, Kolb EA (2007) Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res 13(18 Pt 1): 1226 5446–5454 1227
- Ge J, Liu Y, Li Q, Guo X, Gu L, Ma ZG, Zhu YP (2013) Resveratrol1228induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK.1230Biomed Environ Sci 26(11):902–9111231
- Ghantous A, Sinjab A, Herceg Z, Darwiche N (2013) Parthenolide: from1232plant shoots to cancer roots. Drug Discov Today 18(17–18):1233894–9051234
- Godeke J, Maier S, Eichenmuller M, Muller-Hocker J, von Schweinitz D, Kappler R (2013) Epigallocatechin-3-gallate inhibits 1236 hepatoblastoma growth by reactivating the Wnt inhibitor SFRP1. 1237 Nutr Cancer 65(8):1200–1207 1238
- Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L, Karni R (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71(13):4464–4472 1242
- Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105(11):4163–4169 1252
- HaDuong JH, Martin AA, Skapek SX, Mascarenhas L (2015) Sarcomas. Pediatr Clin N Am 62(1):179–200
- Hassan HT (2004) Ajoene (natural garlic compound): a new antileukaemia agent for AML therapy. Leuk Res 28(7):667–671
- He M, Li Y, Zhang L, Li L, Shen Y, Lin L, Zheng W, Chen L, Bian X, Ng1257HK, Tang L (2014) Curcumin suppresses cell proliferation through
inhibition of the Wnt/beta-catenin signaling pathway in medullo-
blastoma. Oncol Rep 32(1):173–1801259
- Heger M, van Golen RF, Broekgaarden M, Michel MC (2014) The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev 66(1):222–307
 1261 1262 1263 1264
- Hirschfeld S, Ho PT, Smith M, Pazdur R (2003) Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J
 1265

 Clin Oncol 21(6):1066–1073
 1267
- Huang M, Zhang H, Liu T, Tian D, Gu L, Zhou M (2013) Triptolide 1268 inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther 12(2):184–194 1271
- Iciek M, Kwiecien I, Chwatko G, Sokolowska-Jezewicz M, Kowalczyk-
Pachel D, Rokita H (2012) The effects of garlic-derived sulfur com-
pounds on cell proliferation, caspase 3 activity, thiol levels and an-
aerobic sulfur metabolism in human hepatoblastoma HepG2 cells.1272
1273
1274Cell Biochem Funct 30(3):198–2041276
- 1277Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, 1278 Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, 1279Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, 1280Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi 1281AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, 12821283 Pantano Santini D (2015) Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol 12841285
- Johnson DE, Redner RL (2015) An ATRActive future for differentiation therapy in AML. Blood Rev
- Kale AJ, Moore BS (2012) Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem 55(23):10317–10327 12

1286 1287 1288

 $1253 \\ 1254$

1255

Naunyn-Schmiedeberg's Arch Pharmacol

- 1289Kanadzu M, Lu Y, Morimoto K (2006) Dual function of (-)-epigallocat-
echin gallate (EGCG) in healthy human lymphocytes. Cancer Lett
241(2):250–255
- 1292 Kane RC, Farrell AT, Sridhara R, Pazdur R (2006) United States Food
 1293 and Drug Administration approval summary: bortezomib for the
 1294 treatment of progressive multiple myeloma after one prior therapy.
 1295 Clin Cancer Res 12(10):2955–2960
- 1296 Kim CF, Jiang JJ, Leung KN, Fung KP, Lau CB (2009) Inhibitory effects
 1297 of Agaricus blazei extracts on human myeloid leukemia cells. J
 1298 Ethnopharmacol 122(2):320–326
- 1299 Kinahan KE, Sharp LK, Seidel K, Leisenring W, Didwania A, Lacouture
 1300 ME, Stovall M, Haryani A, Robison LL, Krull KR (2012) Scarring,
 1301 disfigurement, and quality of life in long-term survivors of child1302 hood cancer: a report from the Childhood Cancer Survivor study. J
 1303 Clin Oncol 30(20):2466–2474
- Kishida Y, Yoshikawa H, Myoui A (2007) Parthenolide, a natural inhib itor of Nuclear Factor-kappaB, inhibits lung colonization of murine
 osteosarcoma cells. Clin Cancer Res 13(1):59–67
- 1307Koehn FE, Carter GT (2005) The evolving role of natural products in1308drug discovery. Nat Rev Drug Discov 4(3):206–220
- Kumar N, Gangappa D, Gupta G, Karnati R (2014) Chebulagic acid from
 Terminalia chebula causes G1 arrest, inhibits NFkappaB and in duces apoptosis in retinoblastoma cells. BMC Complement Altern
 Med 14:319
- 1313Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macro-1314phages in tumor growth and angiogenesis. J Leukoc Biol131580(4):705-713
- 1316Lee SJ, Langhans SA (2012) Anaphase-promoting complex/cyclosome1317protein Cdc27 is a target for curcumin-induced cell cycle arrest and1318apoptosis. BMC Cancer 12:44
- 1319 Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran
 1320 SA (2011) Curcumin-induced HDAC inhibition and attenuation of
 1321 medulloblastoma growth in vitro and in vivo. BMC Cancer 11:144
- Liao HF, Su SL, Chen YJ, Chou CH, Kuo CD (2007) Norcantharidin
 preferentially induces apoptosis in human leukemic Jurkat cells
 without affecting viability of normal blood mononuclear cells.
 Food Chem Toxicol 45(9):1678–1687
- Liao HF, Chen YJ, Chou CH, Wang FW, Kuo CD (2011) Norcantharidin
 induces cell cycle arrest and inhibits progression of human leukemic
 Jurkat T cells through mitogen-activated protein kinase-mediated
 regulation of interleukin-2 production. Toxicol In Vitro
 25(1):206–212
- Lisle JW, Choi JY, Horton JA, Allen MJ, Damron TA (2008) Metastatic
 osteosarcoma gene expression differs in vitro and in vivo. Clin
 Orthop Relat Res 466(9):2071–2080
- 1334Litten JB, Tomlinson GE (2008) Liver tumors in children. Oncologist133513(7):812-820
- Liu L, Li G, Li Q, Jin Z, Zhang L, Zhou J, Hu X, Zhou T, Chen J, Gao N
 (2013) Triptolide induces apoptosis in human leukemia cells
 through caspase-3-mediated ROCK1 activation and MLC phosphorylation. Cell Death Dis 4:e941
- 1340Liu Y, Bi T, Dai W, Wang G, Qian L, Shen G, Gao Q (2015) Lupeol1341induces apoptosis and cell cycle arrest of human osteosarcoma cells1342through PI3K/AKT/mTOR pathway. Technol Cancer Res Treat
- Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L, Gao Q, Shen G (2015b)
 Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn
 Schmiedeberg's Arch Pharmacol 388(3):295–304
- 1347Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB (2009) Hep1348G2 is a hepatoblastoma-derived cell line. Hum Pathol 40(10):13491512–1515
- 1350Louzao MC, Vieytes MR, Botana LM (2005) Effect of okadaic acid on1351glucose regulation. Mini-Rev Med Chem 5(2):207–215
- 1352Lu S, Gao Y, Huang X, Wang X (2014) Cantharidin exerts anti-1353hepatocellular carcinoma by miR-214 modulating macrophage po-1354larization. Int J Biol Sci 10(4):415–425

- Mann J (2002) Natural products in cancer chemotherapy: past, present 1355 and future. Nat Rev Cancer 2(2):143–148 1356
- Marchiani A, Rozzo C, Fadda A, Delogu G, Ruzza P (2014) Curcumin1357and curcumin-like molecules: from spice to drugs. Curr Med Chem135821(2):204–2221359
- Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E,
Malvar J, Bostrom BC., L. Therapeutic Advances in Childhood1361
1361
1362and C. Lymphoma (2012) Bortezomib with chemotherapy is highly
active in advanced B-precursor acute lymphoblastic leukemia:
Therapeutic Advances in Childhood Leukemia & Lymphoma
(TACL) Study. Blood 120(2): 285–2901360
- Michel MC, Konig G, Mohr K, Simmet T (2005) Editorial guidelines for manuscripts on the pharmacology of plant extracts. Naunyn Schmiedeberg's Arch Pharmacol 371(5):349–350 1368
- Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, 1369
 Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK (2006) Phase I and pharmacokinetic study of 1371
 tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12(17):5207–5215 1374
- Molnar I, Schupp T, Ono M, Zirkle R, Milnamow M, Nowak-Thompson1375B, Engel N, Toupet C, Stratmann A, Cyr DD, Gorlach J, Mayo JM,1376Hu A, Goff S, Schmid J, Ligon JM (2000) The biosynthetic gene1377cluster for the microtubule-stabilizing agents epothilones A and B1378from Sorangium cellulosum So ce90. Chem Biol 7(2):97–1091379
- Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H (2009)1380Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient1381to overcome resistance to TRAIL-mediated apoptosis in
chemoresistant human pancreatic cancer cells. Cancer Res 69(3):13831156–11651384
- Nakabayashi H, Shimizu K (2012) Involvement of Akt/NF-kappaB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer 12:453
- Nam S, Scuto A, Yang F, Chen W, Park S, Yoo HS, Konig H, Bhatia R, Cheng X, Merz KH, Eisenbrand G, Jove R (2012)
 Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol 6(3):276–283
- Nam S, Wen W, Schroeder A, Herrmann A, Yu H, Cheng X, Merz KH, Eisenbrand G, Li H, Yuan YC, Jove R (2013) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol 7(3):369–378
- Niewerth D, Dingjan I, Cloos J, Jansen G, Kaspers G (2013) Proteasome inhibitors in acute leukemia. Expert Rev Anticancer Ther 13(3): 327–337
- Niewerth D, Jansen G, Riethoff LF, van Meerloo J, Kale AJ, Moore BS,
Assaraf YG, Anderl JL, Zweegman S, Kaspers GJ, Cloos J (2014)1401Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A
(Marizomib). Mol Pharmacol 86(1):12–191401
- Nishimura N, Hartomo TB, Pham TV, Lee MJ, Yamamoto T, Morikawa1406S, Hasegawa D, Takeda H, Kawasaki K, Kosaka Y, Yamamoto N,
Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Iijima K,
Matsuo M, Nishio H (2012) Epigallocatechin gallate inhibits sphere
formation of neuroblastoma BE(2)-C cells. Environ Health Prev
Med 17(3):246–2511406
- Noureini SK, Wink M (2012) Antiproliferative effects of crocin in HepG21412cells by telomerase inhibition and hTERT down-regulation. Asian1413Pac J Cancer Prev 13(5):2305–23091414
- Pandey AN (2014) Retinoblastoma: an overview. Saudi J Ophthalmol 1415 28(4):310–315 1416
- Patel D, Shukla S, Gupta S (2007) Apigenin and cancer chemopreven-
tion: progress, potential and promise (review). Int J Oncol 30(1):1417
1418
1419233-2451419

1385

1386

1387

1398

1399

AUTHOR'S PROMP!

Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007)

Nanocarriers as an emerging platform for cancer therapy. Nat

0291420

1421

1422	Nanotechnol 2(12):751–760	Sı
1423	Picone P, Nuzzo D, Caruana L, Messina E, Scafidi V, Di Carlo M (2014)	
1424	Curcumin induces apoptosis in human neuroblastoma cells via inhi-	
1425	bition of AKT and Foxo3a nuclear translocation. Free Radic Res	
1426	48(12):1397–1408	Та
1427	Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B,	
1428	Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll	
1429	M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ,	To
1430	Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson	п
1431	PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A,	Тс
1432	Palladino MA (2011) Marizomib, a proteasome inhibitor for all	10
1433	seasons: preclinical profile and a framework for clinical trials. Curr	
1434	Cancer Drug Targets 11(3):254–284	
1435	Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D	V
1436	(2006) The proteasome inhibitor NPI-0052 is a more effective in-	
1437	ducer of apoptosis than bortezomib in lymphocytes from patients	
1438	with chronic lymphocytic leukemia. Mol Cancer Ther 5(7):	
1439	1836–1843	Va
1440	Safa AR (2012) c-FLIP, a master anti-apoptotic regulator. Exp Oncol	
1440	34(3):176–184	
1442	Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to	V
$1442 \\ 1443$	death's door. Nat Rev Mol Cell Biol 3(6):401–410	
1444	Satomi Y, Nishino H, Shibata S (2005) Glycyrrhetinic acid and related	
$1444 \\ 1445$	compounds induce G1 arrest and apoptosis in human hepatocellular	W
$1445 \\ 1446$	carcinoma HepG2. Anticancer Res 25(6B):4043–4047	
1447	Scherzinger-Laude K, Schonherr C, Lewrick F, Suss R, Francese G,	
1448	Rossler J (2013) Treatment of neuroblastoma and rhabdomyosarco-	
1449	ma using RGD-modified liposomal formulations of patupilone	W
1450	(EPO906). Int J Nanomedicine 8:2197–2211	
1451	Schyschka L, Rudy A, Jeremias I, Barth N, Pettit GR, Vollmar AM	
1452	(2008) Spongistatin 1: a new chemosensitizing marine compound	
1453	that degrades XIAP. Leukemia 22(9):1737–1745	W
1454	Shanmugam MK, Dai X, Kumar AP, Tan BK, Sethi G, Bishayee A	
1455	(2013) Ursolic acid in cancer prevention and treatment: molecular	
1456	targets, pharmacokinetics and clinical studies. Biochem Pharmacol	W
1457	85(11):1579–1587	
1458	Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG,	
1459	Rimoldi M, Biswas SK, Allavena P, Mantovani A (2008)	
1460	Macrophage polarization in tumour progression. Semin	
1461	Cancer Biol 18(5):349–355	W
1462	Simone M, Erba E, Damia G, Vikhanskaya F, Di Francesco AM, Riccardi	•••
1463	R, Bailly C, Cuevas C, Fernandez Sousa-Faro JM, D'Incalci M	
1464	(2005) Variolin B and its derivate deoxy-variolin B: new marine	X
1465	natural compounds with cyclin-dependent kinase inhibitor activity.	Λ
1466	Eur J Cancer 41(15):2366–2377	
1467	Smith MA, Reaman GH (2015) Remaining challenges in childhood can-	V
1468	cer and newer targeted therapeutics. Pediatr Clin N Am 62(1):	Ya
1469	301–312	
1470	Son HS, Kwon HY, Sohn EJ, Lee JH, Woo HJ, Yun M, Kim SH, Kim YC	
1471	(2013) Activation of AMP-activated protein kinase and phosphory-	Ye
1472	lation of glycogen synthase kinase3 beta mediate ursolic acid in-	
1473	duced apoptosis in HepG2 liver cancer cells. Phytother Res	
1474	27(11):1714–1722	
1475	Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS,	Yı
1476	Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies	
1477	SD, Sondel PM (2011) The anti-tumor effect of resveratrol alone or	
1478	in combination with immunotherapy in a neuroblastoma model.	
1479	Cancer Immunol Immunother 60(5):731-738	Zl
1480	Sugantha Priya E, Selvakumar K, Bavithra S, Elumalai P, Arunkumar R,	
1481	Raja Singh P, Brindha Mercy A, Arunakaran J (2014) Anti-cancer	
1482	activity of quercetin in neuroblastoma: an in vitro approach. Neurol	
1409	S-: 25(2)-1(2, 170	71

1483Sci 35(2):163–1701484Sun Y, Xu HJ, Zhao YX, Wang LZ, Sun LR, Wang Z, Sun XF (2013)1485Crocin exhibits antitumor effects on human leukemia HL-60 cells

in vitro and in vivo. Evid Based Complement Alternat Med 2013: 1486 690164 1487

- Sun J, Zhang C, Bao YL, Wu Y, Chen ZL, Yu CL, Huang YX, Sun Y,
 Zheng LH, Wang X, Li YX (2014) Parthenolide-induced apoptosis,
 autophagy and suppression of proliferation in HepG2 cells. Asian
 Pac J Cancer Prev 15(12):4897–4902
- Farleton M, Gilbert J, Sakoff JA, McCluskey A (2012) Synthesis and
 anticancer activity of a series of norcantharidin analogues. Eur J
 Med Chem 54:573–581
- Torbeck R, Pan M, DeMoll E, Levitt J (2014) Cantharidin: a comprehensive review of the clinical literature. Dermatol Online J 20(6) 1496
- Torkin R, Lavoie JF, Kaplan DR, Yeger H (2005) Induction of caspasedependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther 4(1):1–11 1497
- Valdiglesias V, Laffon B, Pasaro E, Cemeli E, Anderson D, Mendez J (2011) Induction of oxidative DNA damage by the marine toxin okadaic acid depends on human cell type. Toxicon 57(6):882–888
- Valdiglesias V, Prego-Faraldo MV, Pasaro E, Mendez J, Laffon B (2013) Okadaic acid: more than a diarrheic toxin. Mar Drugs 11(11): 4328–4349 1506
- Villegas I, Sanchez-Fidalgo S, de la Lastra CA (2011) Chemopreventive
 effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice. Mol Nutr Food Res 55(2):259–267
 1509
- Wallace GCt, Haar CP, Vandergrift WA, Giglio P, Dixon-Mah YN, Varma
 AK, Ray SK, Patel SJ, Banik NL, Das A (2013) Multi-targeted
 DATS prevents tumor progression and promotes apoptosis in ectop ic glioblastoma xenografts in SCID mice via HDAC inhibition. J
 Neurooncol 114(1): 43–50
- Wang IK, Lin-Shiau SY, Lin JK (1999) Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 35(10):1517–1525
 1518
- Watkins R, Wu L, Zhang C, Davis RM, Xu B (2015) Natural productbased nanomedicine: recent advances and issues. Int J Nanomedicine 10:6055–6074

1519

1520

- Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul
 M, Kaur B, Fernandez SA, Chiocca EA, Lawler SE (2011)
 Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments.
 Cancer Res 71(16):5374–5380
 1526
- Wu B, Cui J, Zhang C, Li Z (2012) A polysaccharide from Agaricus 1527
 blazei inhibits proliferation and promotes apoptosis of osteosarcoma cells. Int J Biol Macromol 50(4):1116–1120 1529
- Xiao Z, Hao Y, Liu B, Qian L (2002) Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 43(9):1763–1768
 1532
- Yang L, Liu X, Lu Z, Yuet-Wa Chan J, Zhou L, Fung KP, Wu P, Wu S (2010) Ursolic acid induces doxorubicin-resistant HepG2 cell death via the release of apoptosis-inducing factor. Cancer Lett 298(1):128–138 1535
- Yoshimura K, Ueda N, Ichioka K, Matsui Y, Terai A, Arai Y (2005) Use
 of complementary and alternative medicine by patients with urolog ic cancer: a prospective study at a single Japanese institution.
 Support Care Cancer 13(9):685–690
- Yue GG, Fung KP, Leung PC, Lau CB (2008) Comparative studies on the immunomodulatory and antitumor activities of the different parts of fruiting body of Ganoderma lucidum and Ganoderma spores. Phytother Res 22(10):1282–1291
 1540
- Zheng J, Du W, Song LJ, Zhang R, Sun LG, Chen FG, Wei XT (2014)
 1544

 Norcantharidin induces growth inhibition and apoptosis of glioma
 1545

 cells by blocking the Raf/MEK/ERK pathway. World J Surg Oncol
 1546

 12:207
 1547
- Zhou J, Allred DC, Avis I, Martinez A, Vos MD, Smith L, Treston AM,
 Mulshine JL (2001) Differential expression of the early lung cancer
 detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1
 1550

- (hnRNP-A2/B1) in normal breast and neoplastic breast cancer.Breast Cancer Res Treat 66(3):217–224
- 1553 Zhou X, Lin J, Yin Y, Zhao J, Sun X, Tang K (2007) Ganodermataceae:
 1554 natural products and their related pharmacological functions. Am J
 1555 Chin Med 35(4):559–574
- 1556 Zhu Z, Qian Z, Yan Z, Zhao C, Wang H, Ying G (2013) A phase I
- 1557 pharmacokinetic study of ursolic acid nanoliposomes in healthy
- 1563

volunteers and patients with advanced solid tumors. Int J 1558 Nanomedicine 8:129–136 1559

Zuch D, Giang AH, Shapovalov Y, Schwarz E, Rosier R, O'Keefe R, Eliseev RA (2012) Targeting radioresistant oteosarcoma cells with parthenolide. J Cell Biochem 113(4):1282–1291 1562

unconnection

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

- Q1. Please check if the affiliations are presented correctly.
- Q2. Please check if tables are presented correctly.
- Q3. "De Moerloose, Suciu et al. 2010" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q4. "Rubie, De Bernardi et al. 2011" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q5. "Salerni, Bates et al. 2010" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q6. "Bates, Danilov et al. 2013" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q7. "Geller, Wall et al. 2009" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q8. "Kim, Kang et al. 2013" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q9. "Ma and McLeod 2003" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q10. "Turner, Gururangan et al. 2002" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q11. "Feng, Tang et al. 2013" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q12. "Kushner, Modak et al. 2013" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q13. "Wagner, Hill et al. 2002" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q14. "Najar and Johri 2014" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q15. "Nickel, Keller et al. 2014" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q16. "Sekine, Morais et al. 2014" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q17. "Dreyer, Kadota et al. 2003" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q18. "Graf, van Tinteren et al. 2012" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q19. "Giangaspero, Perilongo et al. 1999" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q20. "Schwab, Westermann et al. 2003" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q21. "Blonski, Taillandier et al. 2012" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q22. "Taylor, Northcott et al. 2012" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q23. "Urbanska, Sokolowska et al. 2014" is cited in text but not given in the reference list. Please provide details in the list or delete the citation from the text.
- Q24. The abbreviation "mRNA" has been expanded to "messenger RNA." Please check if correct.
- Q25. Liu, Bi et al. 2015 has been changed to Liu et al. 2015a, b as per the reference list. Please check if okay.

- Q26. Missing citation for Table 4 was inserted here. Please check if appropriate. Otherwise, please provide citation for Table 4. Note that the order of main citations of tables in the text must be sequential.
- Q27. Please check the sentence starting "The anti-leukemic effects of..." for completeness.
- Q28. Reference [Dechantsreiter et al. 1999] was provided in the reference list; however, this was not mentioned or cited in the manuscript. As a rule, all the references given in the list of references should be cited in the body of a text. Please provide the location of where to insert the reference citation in the main body text.
- Q29. Reference [Peer et al. 2007] was provided in the reference list; however, this was not mentioned or cited in the manuscript. As a rule, all the references given in the list of references should be cited in the body of a text. Please provide the location of where to insert the reference citation in the main body text.

, ist , , to insert,